MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 91832-40-5
MCE 国际站:Cefdinir
产品活性:Cefdinir (FK-482) 是第三代头孢菌素类中的一种半合成的广谱抗生素,被证明对几种革兰氏阴性和革兰氏阳性细菌引起的感染有效。Cefdinir 可用于研究耳,鼻窦,喉咙和皮肤的常见细菌感染。
研究领域:Anti-infection
作用靶点:Bacterial | Antibiotic
In Vitro: Cefdinir (FK-482) is a third generation oral cephalosporin antibiotic. Cefdinir (Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, which is proved to be effective for common bacterial infections of the ear, sinus, throat, and skin. It can be used to treat infections caused by several Gram-negative and Gram-positive bacteria. It is available in US as Omnicef by Abbott Laboratories and in India as Cednir by Abbott, Kefnir by Glenmark and Cefdiel by Ranbaxy. As of 2008, cefdinir was the highest-selling cephalosporin antibiotic in the United States, with more than US$585 million in retail sales of its generic versions alone. Cefdinir (FK-482), a new oral 2-amino-5-thiazolyl cephalosporin, inhibited the luminol-amplified chemiluminescence (LACL) response of human neutrophils stimulated by PMA but not opsonized zymosan, in a concentration-dependent but not time-dependent manner. The LACL response to opsonized zymosan in cytochalasin B-treated neutrophils was, however, inhibited by cefdinir. Furthermore, cefdinir inhibited LACL generation in cell-free systems consisting of H2O2, NaI, and either horseradish peroxidase or a myeloperoxidase-containing neutrophil extract. Orthodianisidine oxidation in these two acellular systems was inhibited by cefdinir.
相关产品:Covalent Screening Library Plus | Natural Product-like Compound Library | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Covalent Screening Library | Antibacterial Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Antibiotics Library | Drug-Induced Liver Injury (DILI) Compound Library | Human Metabolite Library | Off-patent Drug Library | Myricetin 3-O-α-L-arabinopyranoside | (1R,2S,7R)-Sitafloxacin-d4 hydrochloride | Nebacumab | Doxorubicin-13C,d3 TFA | Gepotidacin | Amycolatopsin A | Antibiotic A-33853 | Estradiol hemihydrate | Sulbactam-d2 sodium | Antimicrobial agent-5 | NBTIs-IN-4 | Proanthocyanidins | Anticancer agent 120 | Azlocillin sodium salt | Antitubercular agent-13 | Toyocamycin | Lenampicillin hydrochloride | Hispolon | PC58538 | SPR206 acetate | Caracemide | Antimicrobial agent-10 | Doxycycline calcium | Antibacterial agent 138 | Staurosporine | Dihydrostreptomycin sulfate | Ciclopirox olamine | Rubropunctamine | Topoisomerase IV inhibitor 2 | Psoracorylifol C
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。